Health Care Equipment & Services

Alcon Inc. edges ahead in Zurich’s SMI, boosting the index with a modest gain that steadied Swiss stocks like Swisscom and Nestlé.

Siemens Healthineers AG’s latest outlook cuts revenue growth but lifts earnings due to tariff refunds, while a diagnostics spin‑off aims to boost margins and focus AI‑enabled tech. Discover the key risks, balance‑sheet dynamics, and strategic shifts…

Fresenius partners with Sandoz to launch an emicizumab biosimilar, aiming to boost its rare‑disease pipeline and revenue while navigating regulatory and market challenges.

Swiss market indices stay flat as bond yields rise—insurers and pharma lead the way, while tech lags. Discover how defensive stocks thrive amid shifting macro‑winds and regulatory changes.

VEEVA’s insider sale and Medisights’ AI‑driven oncology study highlight the company’s transparency, AI push and growth potential for data‑governed market insight.

Dexcom insider trades: modest share sales by a board member’s trust and the chief legal officer, fully compliant and routine with no impact on strategy or governance.

Abbott Laboratories continues its 411th quarterly dividend, paying 63¢/share while boosting diagnostics, digital health, and global scale to sustain yields and growth.

Siemens Healthineers expands its Atellica platform with capillary testing, adds AI‑driven diagnostics, and boosts sustainability—transforming in‑vitro diagnostics for faster, patient‑centric care.

UBS keeps Fresenius SE “buy” after fresh analysis: solid dialysis revenue, growing biosimilar mAbxience, digital‑health upside, and clear risk‑mitigation plans.

German DAX gains on falling oil, easing yields, but health‑care stocks face pressure – see how energy cuts boost automotive, tech, and investor alerts for Fresenius.